A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
Decker, Thomas, Overkamp, Friedrich, Rösel, Siegfried, Nusch, Arnd, Göhler, Thomas, Indorf, Martin, Sahlmann, Jörg, Trarbach, TanjaVolume:
17
Language:
english
Journal:
BMC Cancer
DOI:
10.1186/s12885-017-3492-1
Date:
December, 2017
File:
PDF, 545 KB
english, 2017